12 hours ago
Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial
Johnson & Johnson (NYSE:JNJ) ranks among the top stocks for an early retirement portfolio. On June 13, Johnson & Johnson (NYSE:JNJ) announced that patients with relapsed or refractory large B-cell lymphoma (LBCL) showed strong response rates to its investigational dual-targeting CAR T-cell treatment.
Pixabay/Public Domain
According to results given at the 2025 European Hematology Association Congress, the Phase 1b study of JNJ-90014496, a treatment that targets both CD19 and CD20 proteins on cancer cells, showcased complete response rates of 75-80% among assessed patients at the recommended Phase 2 dose. This addition broadens J&J's pharmaceutical portfolio, which has contributed to the company's annual revenue in excess of $89 billion.
Moreover, the suggested Phase 2 dose group showed no signs of Grade 3 or 4 cytokine release syndrome, indicating a favorable safety profile.
Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Read More: and
Disclosure: None.
